New hope for toddlers with rare brain tumors: targeted drug entrectinib tested
NCT ID NCT06528691
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 33 times
Summary
This study tests the drug entrectinib in children under 3 with certain brain tumors (NTRK or ROS1 gene fusions). The goal is to see if the drug can shrink tumors and delay the need for chemotherapy. About 52 children will take entrectinib by mouth, and doctors will monitor tumor response and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GRAACC Hospital (Grupo de Apoio ao Adolescente e à Criança com Câncer)
RECRUITINGSão Paulo, 04039-001, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital Santa Marcelina
RECRUITINGSão Paulo, 08270-070, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital de Câncer de Barretos
RECRUITINGBarretos, São Paulo, 14784400, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Instituto Nacional de Enfermedades Neoplásicas
RECRUITINGLima, Peru
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
King Hussein Cancer Center
RECRUITINGAmman, 11941, Jordan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Entrectinib (Rozlytrek)
What this could lead to
If successful, this could offer a targeted, chemotherapy-sparing option for young children with these rare brain tumors, potentially improving outcomes and reducing side effects.
What could go wrong
This is a small, early-phase trial (52 children) with no control group. The drug may not work for all tumor types, and side effects are possible. Long-term benefits are not yet known.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.